The NHS is preparing to fast-track the introduction of ‘game changing’ new cancer drugs that target tumours according to their genetic make-up. These revolutionary new treatments, called ‘tumour agnostic’ drugs, can be used against a wide range of cancers and could offer hope to patients with rare cancers that may previously have been untreatable. Tumour […]
In this video clip, Professor Eric Jonasch, Medical Oncologist, Division of Cancer Medicine at MD Anderson Cancer Center, University of Texas, Houston, speaks about the role of cytoreductive surgery along with immunotherapy for patients who have metastatic renal cell carcinoma (RCC). Watch the video on Practice Update here
In a recent study, the data from a database were analysed retrospectively to evaluate the onset or worsening of high blood pressure (hypertension) following partial versus radical nephrectomy. 3106 patients who did not have hypertension before nephrectomy had an increased risk of developing hypertension after radical nephrectomy. In 6250 patients who already had hypertension, radical […]
An interim analysis of study Checkmate 920 has shown that patients with advanced renal cell carcinoma (RCC) and brain metastases may benefit from treatment with the ipilimumab/nivolumab combination therapy. The results from this interim analysis were presented at the 2019 American Society of Clinical Oncology (ASCO) in Chicago earlier this month. Read more in Cancer […]
A recent study of patients with solid tumours treated with immune checkpoint inhibitors has shown improved overall survival in patients who had mutations in the genes that code for a group of proteins involved in the way DNA is packaged in the cell (SWI and SNF genes, BRG1/hBRM-associated factor (BAF) and polybromo-BAF (PBAF)). The researchers […]
In a recent study published in Journal of Urology and involving over 100 mostly older patients, almost all of the patients with small kidney tumours never developed advanced cancer or died of the disease during more than 4 years of follow-up in active surveillance. More than half of the patients remained alive without metastatic disease […]
In this video interview from Practice Update, Dr Eric Jonasch, board member for the International Kidney Cancer Coalition (IKCC), talks about the results from the recent global survey involving nearly 2,000 kidney cancer patients. Some of the key findings from this survey were; a significant percentage of patients did not know the histology of their […]
A recent study of 362 patients with brain metastases from renal cell carcinoma (RCC) were treated with stereotactic radiosurgery to remove the metastases. The researchers concluded that stereotactic radiosurgery is highly effective in patients with brain metastases from RCC, and concomitant use of tyrosine kinase inhibitors (TKIs), such as sunitinib and pazopanib, does not suggest […]
Researchers from France have conducted a study to show that metastatic clear cell renal cell carcinoma (RCC) patients who have low expression of PD-L1 also have a long term response to sunitinib. However, low PD-L1 levels suggest a potentially lower impact of immunotherapy in these patients. Read more in Clinical Genitourinary Cancer here
We are delighted to announce that the Scottish Medicines Consortium (SMC), which reviews newly licensed medicines in Scotland, has published advice recommending the routine use of nivolumab plus ipilimumab for intermediate-/poor-risk advanced renal cell carcinoma (RCC) by NHS Scotland. The nivolumab (Opdivo) plus ipilimumab (Yervoy) combination was accepted following consideration through the SMC’s Patient and […]
Copyright 2017 Kidney Cancer Support Network- Douglass Digital | Cambridge Web Design
